The objective of the CHRYSTAL study (Costs and Health Related qualitY of life Study for Type 1 diAbetes meLlitus pediatric patients in Spain) was to shed light upon the social costs of T1DM amongst pediatric patients. 
CONCLUSIONS
• The cost of informal care represents the largest proportion of the social burden associated with T1DM in the pediatric population in Spain.
• An adequate glycemic control (HbA1c <7.5%) and the absence of T1DM related complications or comorbidities appear to be related with significantly lower direct health care costs.
• The results shed light on the current allocation of T1DM related resources, and might enlighten T1DM policy priority setting in Spain.
METHODS
A total of 249 patients were included for analysis (90.5% of all), 26 were excluded because of incomplete information for calculating all the resources identified. Patient characteristics are shown in Table 1 .
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DISCUSSION
This is the first study that estimates the social cost of T1DM in the population under 18 in Spain and, to our knowledge, the first study that estimates the informal cost of T1DM in the population under 18 in the world.
T1DM carries a considerable social economic burden, especially in terms of informal care. This suggests that any program on health promotion and care for T1DM children cannot overlook the importance of informal support networks.
LIMITATIONS
There are two main limitations to our study. First, The 1-year prevalence approach impedes considering long-term complications of T1DM, which are considered the most harmful and costly. Second, informal care time was obtained by recall method, and is thus subject to recall bias. CHRYSTAL is an observational study conducted in 2014 on a representative sample of 275 patients aged 0-17 years diagnosed with T1DM, distributed across 12 randomly selected hospitals from a list of sites that treat diabetic children and adolescents in Spain. 2 The sites were distributed across 8 geographical regions grouping Autonomous Communities (Figure 1 ).
The average annual cost for a T1DM patient was €27,274. 85.1% corresponds to DNHC (€23,204), and 14.9% to DHC (€4,070) ( Figure 2 ).
Medical material and supplies (including glucose meters, insulin pumps, glucose sensors, lancets, blood strips, and other) are the largest DHC (€2,035), followed by Outpatient visits (€841) and Medication (€596) (Figure 3 ).
Informal care represents 97.5% of DNHC (average annual cost of €22,618) ( Figure 4 ). DHC show statistically significant differences depending on glycemic control: €3,616 for children with HbA1c <7.5% and €4,704 for children with HbA1c ≥7.5% (p<0.05) ( Figure 5 ). There are also significant differences depending on the existence of acute and chronic complications (except hypoglycemia) and T1DM related comorbidities: €5,713 for children with complications and/or comorbidities and €3,636 for Inclusion criteria were patients under 18 who had been diagnosed with T1DM for at least 12 months. Patients diagnosed with any other types of diabetes, patients participating in clinical trials and inpatients, were excluded.
Data on demographic characteristics, 12 months retrospective health resource utilization and informal care were collected from medical records and paper questionnaires completed by clinicians and patient´s caregivers.
We used a 1-year prevalence approach and a bottomup costing approach to estimate average annual costs per patient, using 2014 as the base year, from a societal perspective. [3] [4] [5] [6] Direct healthcare costs (DHC):
• The cost of medication (insulin and other medication) was calculated as cost per daily dose multiplied by duration of use. Costs were obtained from the list of approved drugs in Spain 7 .
• The costs of medical material and supplies, healthcare visits, emergency services, and tests were calculated by multiplying resource quantities by the average of all available official regional unit costs. 7, 8 • Hospitalization costs were obtained by their main Diagnosis-Related Group (DRG). 9
Direct non-healthcare costs (DNHC):
• The costs of informal care, defined as the time used in performing tasks that help maintain or enhance the patient´s health, were calculated by the proxy good method, which uses the cost of a professional caregiver as a proxy for the time provided by informal caregivers. 10 The maximum daily informal care time per patient was limited to 8 hours in order to avoid joint-production bias when reported care time exceeded 8 hours (this affected 5% of the sample). 10 • Families´expenditure on transportation, special food and physical activity undertaken because of the child´s T1DM were provided by the caregiver.
Results were analyzed by glycemic control (HbA1c <7.5% vs HbA1c ≥7.5%) 11 and by the presence or absence of T1DM related complications and/or comorbidities (ketosis without acidosis, ketoacidosis, dawn phenomenon, retinopathy, nephropathy, peripheral neuropathy, hypothyroidism and celiac disease). (Figure 6 ). Both tests were calculated controlling for age and gender. 12 
